ATLAS PHARMACEUTICALS
0712.536.660 · rovalta.com · 25/09/2026
ATLAS PHARMACEUTICALS
Company — Normal situation.
Financial year 2024 · Closed on 14/06/2024
Overview
Identity
Source · BCE/KBOATLAS PHARMACEUTICALS is a company registered in Belgium.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0712.536.660
- Legal form
- Private limited company
- Latest accounts
- 14/06/2024
Financials
Source · NBB, 6 filingsTrend over 4 financial years
| 2024 | 2023 | 2022 | 2021 | ||||
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Gross margin | 132,4 k € | +2018% | -6,9 k € | -38.8% | -5 k € | +96.9% | -158,1 k € |
| EBITDA | 132,3 k € | +1818% | -7,7 k € | -17.2% | -6,6 k € | +96.2% | -172,9 k € |
| Operating result | 96,8 k € | +1357% | -7,7 k € | -17.2% | -6,6 k € | +96.2% | -172,9 k € |
| Net result | 96,6 k € | +1634% | -6,3 k € | +6.0% | -6,7 k € | +96.1% | -173 k € |
| Balance sheet | |||||||
| Equity | – | 1,8 k € | -77.3% | 8,1 k € | -45.1% | 14,8 k € | |
| Total assets | 98,4 k € | +168% | 36,7 k € | -15.2% | 43,3 k € | +146% | 17,6 k € |
| Cash | 96,9 k € | +28769% | 335,6 € | -92.6% | 4,5 k € | -74.1% | 17,4 k € |
| Debts | 98,4 k € | +183% | 34,8 k € | +4.5% | 33,3 k € | +1114% | 2,7 k € |
Board of directors
Source · NBB, accounts to 14/06/20242 active · 4 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 14/06/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 6 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 20/06/2024 | 20/06/2024 | 29/09/2023 | 30/09/2022 | 14/09/2021 | 30/09/2020 |
| General meeting | 14/06/2024 | 15/04/2024 | 30/08/2023 | 29/09/2022 | 07/09/2021 | 27/09/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 6 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 14/06/2024 | 14/06/2024 | 20/06/2024 | Dutch | |
| Abridged model | 31/12/2023 | 15/04/2024 | 20/06/2024 | Dutch | |
| Abridged model | 31/12/2022 | 30/08/2023 | 29/09/2023 | Dutch | |
| Abridged model | 31/12/2021 | 29/09/2022 | 30/09/2022 | Dutch | |
| Abridged model | 31/12/2020 | 07/09/2021 | 14/09/2021 | Dutch | |
| Abridged model | 31/12/2019 | 27/09/2020 | 30/09/2020 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 14/06/20242 active · 4 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official GazetteSimilar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202496,6 k €↑
- 2023Annual accounts 2023-6,3 k €↑
- 2022Annual accounts 2022-6,7 k €↑
- 2021Annual accounts 2021-173 k €